Connectus Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Connectus Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-17,959	Closed	-$7.31M	–	523
2023 Q4	$7.31M	Buy	17,959 +3,706	+26%	+$1.37M	0.15%	136
2023 Q3	$4.96M	Buy	14,253 +4,118	+41%	+$1.44M	0.11%	164
2023 Q2	$3.57M	Buy	10,135 +552	+6%	+$186K	0.08%	167
2023 Q1	$3.02M	Buy	9,583 +115	+1%	+$34.5K	0.07%	187
2022 Q4	$2.73M	Buy	9,468 +86	+0.9%	+$26.2K	0.06%	183
2022 Q3	$2.72M	Buy	9,382 +942	+11%	+$271K	0.06%	232
2022 Q2	$2.38M	Buy	+8,440	New	+$2.26M	0.05%	197
2022 Q1	–	Sell	-3,232	Closed	-$710K	–	415
2021 Q4	$710K	Buy	+3,232	New	+$628K	0.03%	244

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Connectus Wealth's VRTX Position: Q1 2024 in Review

Connectus Wealth sold out of Vertex Pharmaceuticals (VRTX) in Q1 2024, closing a stake of 17,959 shares — an estimated $7.31M sold.

Connectus Wealth first reported a position in VRTX in Q4 2021 and held it in 8 quarters. The position peaked at $7.31M in Q4 2023. 1,493 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

Connectus Wealth reported no remaining Vertex Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Connectus Wealth sold 17,959 Vertex Pharmaceuticals shares in Q1 2024, an estimated $7.31M.
Connectus Wealth first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 8 quarters.
Connectus Wealth's Vertex Pharmaceuticals position peaked at $7.31M in Q4 2023.
1,493 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Connectus Wealth's 13F filing for Q1 2024, filed 14 May 2024.